|
|
News Breaks | | | | October 15, 2012 | | 08:58 EDT |  | AEGR | Aegerion gaps higher in early trading, levels to watch
The shares are up ahead of an expected FDA panel release of briefing documents for Lomitapide. The vote on approving the drug would be on October 17th. At the current price of $17.55, next resistance is at $18.61. Support is at $17.20. | |
|
News For AEGR From The Last 14 Days Check below for free stories on AEGR the last two weeks. |
|
|
| May 23, 2013 | | 11:55 EDT |  | AEGR | Options with decreasing implied volatility: AEGR PXP AMRN DSX ACT
 Subscribe for More Information | | | May 20, 2013 | | 07:29 EDT |  | AEGR | Aegerion price target raised to $77 from $65 at Lazard Capital
Subscribe for More Information | | | May 17, 2013 | | 12:28 EDT | | AEGR | Options with increasing implied volatility: SCTY AEGR NCT LYV
Subscribe for More Information | | | 07:18 EDT | | AEGR | Aegerion price target raised to $65 from $50 at Leerink
Subscribe for More Information | | | May 16, 2013 | | 16:29 EDT |  | AEGR | On The Fly: Closing Wrap
Stocks on Wall Street were lower following some disappointing economic data and a hint from a regional Fed president that the central bank may taper its easing program in the coming months. The averages traded in a narrow range for much of the session before moving lower in the final hour of trading. Comments by San Francisco Fed president John Williams late in the afternoon, suggesting that the central bank may begin slowing its bond buying pace by the summer, may have spurred the late session selling. ECONOMIC EVENTS: In the U.S., initial jobless claims rose 32K to 360K last week, compared to expectations for them to remain relatively stable at 330K. The consumer price index dropped a larger than forecast 0.4% in April, though the "core" CPI rate rose 0.1%, as expected. Housing starts were down 16.5% in April from the prior month, versus an expected decrease of 6.4%, though building permits jumped 14.3% from the prior month, beating an expected increase of 3.8%. The Philadelphia Fed General Business Conditions Index for May came in at -5.2, versus expectations for a +2.2 reading. COMPANY NEWS: Earnings reports from two Dow members, Wal-Mart (WMT) and Cisco (CSCO), sent their shares in opposite directions. Cisco shares added $2.66, or 12.54%, to $23.87 to lead the blue chip index after the company's results beat expectations on the top and bottom lines. Wal-Mart fell $1.36, or 1.7%, to $78.50 after its first quarter earnings sand second quarter outlook missed the consensus forecast... Tesla Motors (TSLA) last night announced a stock and debt offering of more than $800M, with CEO Elon Musk announcing his intent to buy $100M of the offering, and shares of the electric car maker added $7.36, or 8.67%, to $92.20. MAJOR MOVERS: Among notable gainers was Aegerion (AEGR), up $14.73, or 31.37%, to $61.70 after the company said its Juxtapid treatment may have a $1B global market opportunity and at least two analyst firms raised their price targets on its shares. Also higher was Constellation Brands (STZ), up $1.52, or 3.03%, to $51.76 after the stock was upgraded at Stifel and ISI Group. Among noteworthy losers following analyst downgrades were AMD (AMD), which fell 55c, or 12.56%, to $3.83 after Goldman downgraded the stock to Sell, and CSC (CSC), which slid $2.12, or 4.74%, to $42.59 after being cut to Hold at Deutsche Bank. Also lower following its quarterly report was NetQin Mobile (NQ), down 72c, or 7.5%, to $8.88. INDICES: The Dow was down 42.47, or 0.28%, to 15,233.22; the Nasdaq was down 6.38, or 0.18%, to 3,465.24; and the S&P 500 was down 8.31, or 0.50%, to 1,650.47. | | | 15:28 EDT |  | AEGR | Aegerion surges after bullish projection on Juxtapid potential
Subscribe for More Information | | | 14:41 EDT | | AEGR | Aegerion price target raised to $85 from $52 at Deutsche Bank
Subscribe for More Information | | | 09:49 EDT | | AEGR | Aegerion price target raised to $58 from $50 at BofA/Merrill
BofA/Merrill raised Aegerion's price target and estimates following CEO comments at its healthcare conference. The CEO noted mid-Q2 trends continue to accelerate and that discontinuation rates are very low. The firm rates shares a Buy. | | | 07:29 EDT |  | AEGR | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 14, 2013 | | 11:39 EDT | | AEGR | High option volume stocks: IVZ BGCP SCTY DNR AEGR
Subscribe for More Information | | |
|
|
|
|
|
|
